Qatari German Company for Medical Devices (Q.P.S.C.)(QGMD.QA)
No price history available.
Key financial summary
Financials in QAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | QARm | 25 | 41 | 43 | 28 | 10 | 5 | N/A | N/A |
| Operating profit | QARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | QARm | 1 | 1 | 1 | 1 | -68 | 9 | N/A | N/A |
| EPS reported | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | QARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | QARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | QARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | QAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in QAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Qatari German Company for Medical Devices (Q.P.S.C.), operating from its headquarters in Doha, Qatar, was established in 2000. This company primarily focuses on the manufacturing and sale of single-use, disposable syringes across the Middle East. Its diverse product line features the Q JectUltra insulin syringe for diabetes care, the Q Flow series for infusion therapy, the Q Need disposable hypodermic needle, the Q Ject syringe for dispensing curative medications, and the Q Safe, an innovative syringe designed to prevent reuse. Additionally, the firm engages in the trade of various medical equipment, tools, and general supplies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Qatari German Company for Medical Devices (Q.P.S.C.) (QGMD.QA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Qatari German Company for Medical Devices (Q.P.S.C.), operating from its headquarters in Doha, Qatar, was established in 2000. This company primarily focuses on the manufacturing and sale of single-use, disposable syringes across the Middle East. Its diverse product line features the Q JectUltra insulin syringe for diabetes care, the Q Flow series for infusion therapy, the Q Need disposable hypodermic needle, the Q Ject syringe for dispensing curative medications, and the Q Safe, an innovative syringe designed to prevent reuse. Additionally, the firm engages in the trade of various medical equipment, tools, and general supplies.